{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Zhu C"],"funding":["CSCO-hengrui Cancer Research Fund","CAMS Innovation Fund for Medical Sciences (CIFMS)","National High Level Hospital Clinical Research Funding","CAMS Innovation Fund for Medical Sciences","CSCO-MSD Cancer Research Fund","National Ten-thousand Talent Program"],"pagination":["56"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11149318"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["12(1)"],"pubmed_abstract":["<h4>Background</h4>Accumulating evidence suggests that the gut microbiota and metabolites can modulate tumor responses to immunotherapy; however, limited data has been reported on biliary tract cancer (BTC). This study used metagenomics and metabolomics to identify characteristics of the gut microbiome and metabolites in immunotherapy-treated BTC and their potential as prognostic and predictive biomarkers.<h4>Methods</h4>This prospective cohort study enrolled 88 patients with BTC who received PD-1/PD-L1 inhibitors from November 2018 to May 2022. The microbiota and metabolites significantly enriched in different immunotherapy response groups were identified through metagenomics and LC-MS/MS. Associations between microbiota and metabolites, microbiota and clinical factors, and metabolites an"],"journal":["Biomarker research"],"pubmed_title":["Gut microbiota and metabolites signatures of clinical response in anti-PD-1/PD-L1 based immunotherapy of biliary tract cancer."],"pmcid":["PMC11149318"],"funding_grant_id":["2022-I2M-C&T-A-003","NA","Y-HR2020QN-0414","2021-I2M-1-061","2022-PUMCH-B-128","2022-I2M-C&amp;T-A-003","Y-HR2020MS-0415","Y-HR2019-0239","Y-MSDZD2021-0213","2021-I2M-1-003"],"pubmed_authors":["Ning C","Zhang D","Xun Z","Liang Y","Chao J","Long J","Zhang N","Zhang L","Wang H","Zhu C","Lan Z","Yang X","Sang X","Wang S","Jiang X","Wang Y","Zhu R","Xue J","Zhang C","Zhao H"],"additional_accession":[]},"is_claimable":false,"name":"Gut microbiota and metabolites signatures of clinical response in anti-PD-1/PD-L1 based immunotherapy of biliary tract cancer.","description":"<h4>Background</h4>Accumulating evidence suggests that the gut microbiota and metabolites can modulate tumor responses to immunotherapy; however, limited data has been reported on biliary tract cancer (BTC). This study used metagenomics and metabolomics to identify characteristics of the gut microbiome and metabolites in immunotherapy-treated BTC and their potential as prognostic and predictive biomarkers.<h4>Methods</h4>This prospective cohort study enrolled 88 patients with BTC who received PD-1/PD-L1 inhibitors from November 2018 to May 2022. The microbiota and metabolites significantly enriched in different immunotherapy response groups were identified through metagenomics and LC-MS/MS. Associations between microbiota and metabolites, microbiota and clinical factors, and metabolites an","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Jun","modification":"2026-05-03T03:29:00.626Z","creation":"2026-04-07T18:48:04.001Z"},"accession":"S-EPMC11149318","cross_references":{"pubmed":["38831368"],"doi":["10.1186/s40364-024-00607-8"]}}